Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

CRISPR and MaxCyte sign licensing deal for cancer therapies

pharmaceutical-technologyNovember 13, 2018

Tag: CRISPR , MaxCyte , cancer therapies

PharmaSources Customer Service